Ensign Peak Advisors
CABA icon

Ensign Peak Advisors’s Cabaletta Bio CABA Stock Holding History

Ensign Peak Advisors’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-550,000
Closed -$1.2M – 1711
2025
Q4 		$1.2M Buy
+550,000
New +$1.36M ﹤0.01% 783
2024
Q4 		– Sell
-36,873
Closed -$174K – 1711
2024
Q3 		$174K Buy
36,873
+17,500
+90% +$101K ﹤0.01% 1695
2024
Q2 		$145K Sell
19,373
-311,552
-94% -$3.82M ﹤0.01% 1704
2024
Q1 		$5.65M Buy
330,925
+212,923
+180% +$4.57M 0.01% 600
2023
Q4 		$2.68M Buy
+118,002
New +$1.98M 0.01% 806
2020
Q3 		– Sell
-8,075
Closed -$90K – 1747
2020
Q2 		$90K Hold
8,075
– – ﹤0.01% 1635
2020
Q1 		$59K Sell
8,075
-16,925
-68% -$232K ﹤0.01% 1599
2019
Q4 		$349K Buy
+25,000
New +$296K ﹤0.01% 1567

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Ensign Peak Advisors's CABA Position: Q1 2026 in Review

Ensign Peak Advisors sold out of Cabaletta Bio (CABA) in Q1 2026, closing a stake of 550,000 shares — an estimated $1.2M sold.

Ensign Peak Advisors first reported a position in CABA in Q4 2019 and held it in 8 quarters. The position peaked at $5.65M in Q1 2024. 108 funds tracked by Wall St. Rank hold CABA as of Q1 2026.

  • Ensign Peak Advisors reported no remaining Cabaletta Bio position as of Q1 2026 after selling out during the quarter.
  • Ensign Peak Advisors sold 550,000 Cabaletta Bio shares in Q1 2026, an estimated $1.2M.
  • Ensign Peak Advisors first reported a position in Cabaletta Bio in Q4 2019 and held it in 8 quarters.
  • Ensign Peak Advisors's Cabaletta Bio position peaked at $5.65M in Q1 2024.
  • 108 funds tracked by Wall St. Rank held Cabaletta Bio as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.